December 20th 2024
Low-level light therapy for dry eye disease and chalazion
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
Illuminating the Power of Collaborative Care in nAMD and DME: Advancing the Shift to Treatment Innovations
February 2, 2025
Register Now!
EnVision Summit
February 14-17, 2025
Register Now!
Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
March 9, 2025
Register Now!
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
CRU Eye Symposium
March 28-30, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
19th Annual Controversies in Modern Eye Care
May 4, 2025
Register Now!
(CME Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
Intraductal meibomian gland probing reduces inflammation
September 1st 2009A new technique of intraductal meibomian gland probing using disposable cannulas of various lengths appears highly effective in providing quick and lasting relief from inflammatory sysmptoms of obstructive meibomian gland disease.
New options in treating lid wiper epitheliopathy
September 1st 2009An oil-in-water and a corticosteroid were both effective in eliminating the signs and symptoms of lid wiper epitheliopathy after a 1-month active treatment phase in a recent study. Improvement was effectively maintained with the emollient eye drops in all patients over a 12-month period.
Cyclosporine helps prevent progression of dry eye
September 1st 2009A recent study showed that moderate to sever dry eye disease can be best treated with anti-inflammatory medications such as topical cyclosporine. According to one ophthalmologist, cyclosporine can significantly limit progression of dry eye disease and should be considered a 'go-to' therapy for this patient population.
Inflammation thwarts corneal transplants in herpes patients
July 8th 2009A further study in the July issue of Ophthalmology, the journal of the American Academy of Ophthalmology, investigated inflammation biomarkers in relation to corneal transplant rejection in herpes simplex patients. Its results have shown that inflammation thwarts corneal transplants.
Non invasive ocular drug delivery trial promising for dry eye
June 10th 2009In a dry eye Phase II clinical trial EyeGate Pharma reports that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES).
TearLab Osmolarity System cleared by FDA
May 21st 2009The TearLab Osmolarity System is intended to measure the osmolarity of human tears to aid in the diagnosis of patients with signs or symptoms of Dry Eye Disease (DED) in conjunction with other methods of clinical evaluation. It is now in a position to be marketed to clinincal facilities in the United States, having received its FDA 510(k) clearance.
World's largest eye bank launches research institute
May 13th 2009The world's largest eye bank, The Tampa Lions Eye Institute for Transplant and Research, Inc. in Florida, which has supplied over 30,000 corneas for transplant and 50,000 eyes for research worldwide over the past 30 years, is to open a state-of-the-art research facility.
Gene silencing may help corneal transplantation
April 15th 2009The side effects of an experimental 'gene-silencing' treatment that is currently being investigated for a variety of diseases could be useful in corneal transplantation, where growth of new blood and lymph vessels is believed to be a major cause of graft failure.
Patient enrolment completed for prevention of corneal transplant rejection trial
March 25th 2009Lux Biosciences has just completed its enrolment in the company's Phase III LUCIDA (LUx Corneal Transplant Implant Development and Advancement of Therapy) clinical trial programme for LUMITECT (LX201), a silicone matrix ocular (episcleral) implant designed to provide the continuous release for one year of therapeutic levels of cyclosporine A locally to the eye to prevent corneal transplant rejection.
Testing dry eye diagnostic system
March 18th 2009The TearLab Osmolarity Core Validation Study, a multicentre international clinical study assessing the efficacy of the TearLab Osmolarity System for the diagnosis of dry eye disease, has been launched by the system's maker, OccuLogix Inc, and sponsored by Alcon.